Shire acquires ViroPharma in $4.2 billion orphan drug deal

12-11-2013

Shire acquires ViroPharma in $4.2 billion orphan drug deal

UK-based drugmaker Shire plc announced on November 11 that it had acquired rare disease biopharmaceutical company ViroPharma in an agreement worth approximately $4.2 billion.


Shire, ViroPharma, acquisition, Cinryze

LSIPR